Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 3:20 p.m. ET. A live webcast of the presentation will be available, with an archived version accessible until November 30, 2021. Daré focuses on innovative products for women's health, with a portfolio including potential first-in-category therapies like Ovaprene® and Sildenafil Cream, 3.6%. The company aims to enhance treatment options in contraception, fertility, and sexual health.

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference being held November 15-17, 2021.

Date:	Tuesday, November 16th
Time:	3:20 p.m. ET
Presenter:	Sabrina Martucci Johnson, President and Chief Executive Officer
Live webcast:	https://wsw.com/webcast/stifel58/dare/1859760

An archived webcast of Ms. Johnson’s presentation will be available following the event until November 30, 2021 under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.

Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake.robison@canalecomm.com
619.849.5383

Source: Daré Bioscience, Inc.

FAQ

When will Daré Bioscience present at the Stifel 2021 Virtual Healthcare Conference?

Daré Bioscience will present on November 16, 2021, at 3:20 p.m. ET.

Who is presenting for Daré Bioscience at the conference?

Sabrina Martucci Johnson, the President and CEO, will present.

How can I watch Daré Bioscience's conference presentation?

You can watch the live webcast at https://wsw.com/webcast/stifel58/dare/1859760.

Will there be an archived version of the presentation by Daré Bioscience?

Yes, an archived version will be available until November 30, 2021.

What are the focus areas of Daré Bioscience?

Daré Bioscience focuses on women's health, primarily in contraception, fertility, and sexual health.

What products are in Daré Bioscience's portfolio?

Daré's portfolio includes Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1.